News, Resources, Updates
A scientific hub to keep you informed about our latest research and company updates.
![Proven Compound Susceptible Tau[P301S] Mouse Model for Preclinical Proof of Concept](https://www.innoserlaboratories.com/wp-content/uploads/2026/03/Proven-Compound-susceptible-TauP301S-mouse-model-for-preclinical-proof-of-concept--400x250.png)
Proven Compound Susceptible Tau[P301S] Mouse Model for Preclinical Proof of Concept
The Tau[P301S] mouse remains one of the most established in vivo models for evaluating therapeutics targeting tauopathies including Alzheimer's disease and frontotemporal dementia (FTD). Presented at AD/PD 2025 in Vienna, this poster provides comprehensive...
InnoSer Presents New Data at the 8th CKD Summit 2026: Advancing Preclinical Models for ADPKD Research
Next week, the kidney research community will gather in Boston for the 8th CKD Summit 2026, a premier event that brings together clinicians, researchers, and industry experts to discuss the latest advances in chronic kidney disease (CKD) research and therapy...
Home-Cage Behavior Discriminates Neurodegeneration Models from Healthy Aging Mice
Distinguishing pathological neurodegeneration from normal biological aging is a fundamental challenge in preclinical neuroscience. Presented at AD/PD 2023 in Gothenburg, this poster — developed in collaboration with Sylics and VU University Amsterdam — establishes a...
High-Fat Cholesterol and Fructose Diet Induces Cognitive Deficits in a Mouse Model of NAFLD
Epidemiological evidence suggests that western-style diet and the resulting non-alcoholic fatty liver disease (NAFLD) negatively impact cognitive performance, yet this relationship had not been formally investigated in a mouse model. Presented at the 6th Global NASH...
Full Phenotypic Characterization of an Adult-Onset ADPKD Mouse Model for Extended Disease Monitoring of Novel ADPKD Therapeutics
Autosomal dominant polycystic kidney disease (ADPKD) shows heterogeneous disease onset and progression in patients, demanding preclinical models that capture the full natural history of the condition. Presented at the 8th CKD Drug Development Summit in Boston (2026),...
Early Phenotypic Characterization of TDP-43 Q331K Mouse Model of ALS Reveals Elevated Plasma Neurofilament Light, Nerve Conduction Abnormalities and Behavioral Deficits
TDP-43 pathology underlies 97% of all ALS cases, making the TDP-43(Q331K) transgenic mouse a clinically relevant preclinical tool. Presented at SfN Neuroscience 2025 in San Diego, this poster provides longitudinal phenotypic characterization of female TDP-43(Q331K)...
info@innoserlaboratories.com